Download Files:
RIDR-PI-103
$200 – $2,250
Products Details
Product Description
– RIDR-PI-103 is a reactive oxygen species (ROS)-induced agent release proagent with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2].
Web ID
– HY-144876
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C27H25N7O4
References
– [1]Mishra R, et al. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci. 2021;22(4):2088. Published 2021 Feb 19. |[2]Rosalin Mishra, et al. Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-10-04.
CAS Number
– 2581114-71-6
Molecular Weight
– 511.53
Compound Purity
– 98.02
SMILES
– O=C(CN)NC1=CC(N)=CC=C1OC2=CC=CC(C3=NC4=C(C(N5CCOCC5)=N3)OC6=NC=CC=C64)=C2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Reactive Oxygen Species
Pathway
– Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
